Evidence analysisOctober 16, 2026Health & Science
Human medicines European public assessment report (EPAR): Neuzafy, filgrastim, Status: Opinion

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
New Medicines and Opinions: Neuzafy (filgrastim)
What is established
Neuzafy is a biosimilar medicinal product containing filgrastim, a recombinant granulocyte colony-stimulating factor (G-CSF). Filgrastim works by stimulating the bone marrow to increase production and maturation of neutrophils, a type of white blood cell important in fighting infections. Its active mechanism targets the G-CSF receptor to enhance neutrophil counts.
Filgrastim is used primarily to treat neutropenia (a low neutrophil count) especially in patients undergoing chemotherapy for cancer, as well as in those receiving myeloablative therapy followed by bone marrow transplantation. It is also utilized to mobilize peripheral blood progenitor cells (PBPCs).
Neuzafy has been evaluated by the European Medicines Agency (EMA) and recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) as of October 15, 2026. It is considered highly similar in quality, safety, and efficacy to the reference product Neupogen, another filgrastim preparation authorized in Europe.
The marketing authorization application was submitted by CuraTeQ Biologics (Malta) Limited. Neuzafy is supplied in solution form for injection or infusion at concentrations of 30 MU/0.5 ml and 48 MU/0.5 ml.
What the source claims
- Neuzafy reduces the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancies, excluding chronic myeloid leukemia and myelodysplastic syndromes.
- It decreases neutropenia duration in patients undergoing myeloablative therapy with subsequent bone marrow transplantation who are at risk of severe prolonged neutropenia.
- The safety and efficacy profile of Neuzafy applies similarly to adults and children receiving chemotherapy.
- Neuzafy mobilizes peripheral blood progenitor cells (PBPCs) effectively.
- Long-term administration is indicated for patients with severe congenital, cyclic, or idiopathic neutropenia with specific absolute neutrophil count thresholds and recurrent infections, to increase neutrophil counts and reduce infection.
- It is also indicated for persistent neutropenia in advanced HIV patients when other management options are inappropriate, to reduce bacterial infection risk.
- Administration is recommended to be under the supervision of experienced oncology and hematology clinicians.
What may be missing from the usual framing
The available EMA opinion focuses on regulatory and clinical efficacy elements typical for approval processes but does not analyze broader contexts that influence uptake, cost, and access. For example, the dossier does not explicitly discuss:
- Comparative cost-effectiveness versus other filgrastim biosimilars or originator products.
- Health system considerations such as inclusion within treatment protocols across different EU countries.
- Potential real-world variations in safety or efficacy due to diverse patient populations or treatment settings not fully represented in clinical trials.
- Long-term safety data post-marketing surveillance, which may influence clinician confidence and patient outcomes.
- Patient-centered outcomes like quality of life improvements or adverse event tolerability.
This material is not present in the EMA summary but may be accessible through subsequent studies, health technology assessments, or pharmacovigilance reports.
Competing evidence or uncertainty
The EMA assessment emphasizes biosimilarity based on comparability to the reference filgrastim, Neupogen, with no indication of major clinical divergence. However, the following areas remain subject to standard uncertainty:
- Long-term comparative effectiveness and safety: Biosimilar approvals rely on similarity principles combined with clinical data, but rare adverse effects or efficacy nuances may emerge only through extensive clinical use.
- Differentials in immune response: As a recombinant protein, immunogenicity potential differs by patient; localized real-world data collection can further elucidate this risk.
- Use in pediatric versus adult populations: Though safety and efficacy are noted as similar, pediatric patients often require more detailed study to identify unique responses or dosing considerations.
- Patient populations excluded: The indication explicitly excludes certain hematologic malignancies like chronic myeloid leukemia and myelodysplastic syndromes, limiting generalizability to those groups.
- Potential for off-label use: The manufacture and physician experience may influence how readily Neuzafy is adopted outside the formal indications, with variable monitoring.
Further independent studies, post-marketing surveillance data, and comparative effectiveness research will clarify these uncertainties.
Why it matters
Neutropenia is a serious clinical problem, increasing vulnerability to infection which can be life-threatening in patients undergoing chemotherapy or stem cell transplantation. Medicines that effectively reduce neutropenia duration and complications like febrile neutropenia are critical in oncology support care. As a biosimilar, Neuzafy has the potential to offer a clinically equivalent but potentially more affordable alternative to established reference agents.
Access to biosimilar filgrastim options may enhance healthcare sustainability by introducing market competition, potentially lowering costs and broadening patient access. This is particularly important in resource-constrained settings or healthcare systems seeking cost containment without sacrificing treatment quality.
Moreover, the inclusion of indications such as in severe congenital neutropenias and advanced HIV infection expands treatment opportunities for vulnerable groups with limited options.
Ensuring that physicians experienced in hematology and oncology supervise Neuzafy usage aligns with the complexity and risk profile of neutropenia management, safeguarding patient safety and maximizing therapeutic benefit.
What to verify next
- Review the full Summary of Product Characteristics (SmPC) once published by EMA for detailed guidance on dosage, contraindications, adverse effects, and administration protocols.
- Monitor post-authorization safety reports and pharmacovigilance data for any emergent safety signals or real-world effectiveness evidence.
- Compare pricing and reimbursement status of Neuzafy across different EU member states in relation to other filgrastim products.
- Seek independent clinical studies or health technology assessments evaluating Neuzafy’s effectiveness, immunogenicity, and patient-reported outcomes.
- Evaluate how medical guidelines and oncology protocols integrate Neuzafy into treatment algorithms over time.
- Check for updates on pediatric use and long-term safety data that could influence wider adoption.
Readers interested in the most authoritative and detailed information should consult the original EMA source page and documentation on Neuzafy.
Source & verification
Primary source: New medicines and opinions: human · October 16, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Burkina Faso Targets Critics in Exile
Accountability in Burkina Faso: Evidence Dossier on Judicial Repression of Critics Abroad What is established Since a military coup in September 2022, the ruling…

Human Rights Watch Mourns Death of Activist Nabeel Rajab
Human Rights Evidence Dossier: The Life and Legacy of Nabeel Rajab What is established Nabeel Rajab, a Bahraini human rights activist well-known for his…

Two more journalists murdered in Latin America, prompting press freedom concerns
Two More Journalists Murdered in Latin America: Press Freedom Under Threat In November 2026, Latin America witnessed a violent escalation against the press with…